I respectfully and strongly disagree! The study has enrolled over 1300 patients, and the study itself does not over stratify. Yes they designed a study that 32% diabetic, it will have difficult lesions, but that is not over stratification. Now many people are going to poor over certain subsets, one being insulin dependent diabetics. A lot of post analysis will be done. Old technology? What? BSX has Taxus Liberte in Europe, but in the U.S. Liberte is out 16 to 19 months. Unless I have missed it I have not seen an announcement of having completed enrollment. JNJ is at least out 24 months. In Cardiology that is a long time! What do you mean when it is completed? It has been completed for a long time. The better question is why JNJ has held up the results. I will re-state my point however, and that is unless Reality shows a major advantage of one over the other, most docs have made up there minds on what they are going to use. I respectfully disagree.